Prophylaxis escalation in severe von Willebrand disease: A prospective study from the von Willebrand Disease Prophylaxis Network by Abshire, T.C. (Thomas Calvin) et al.
IN FOCUS
Prophylaxis escalation in severe von Willebrand disease: a
prospective study from the von Willebrand Disease
Prophylaxis Network
T . ABSH IRE ,* J . COX-G ILL ,† C. L . KEMPTON,‡§ F . W. G . LEEBEEK , ¶ M. CARCAO,** P . KOUIDES ,††
S . DONF IELD‡‡ and E . BERNTORP§§
*Blood Research Institute and Departments of Pediatrics and Medicine, Medical College of Wisconsin; †Pediatric Hematology, Medical
College of Wisconsin, Comprehensive Center for Bleeding Disorders, BloodCenter of Wisconsin, Milwaukee, WI; ‡Aflac Cancer and Blood
Disorders Center, Children’s Healthcare of Atlanta and Emory University; §Department of Hematology and Medical Oncology, Emory
University, Atlanta, GA, USA; ¶Department of Hematology, Erasmus University Medical Center, Rotterdam, the Netherlands; **Department of
Paediatrics, Division of Haematology/Oncology, Hospital for Sick Children, Toronto, ON, Canada; ††Department of Medicine, Rochester
General Hospital, Rochester, NY; ‡‡Department of Biostatistics, Rho, Inc., Chapel Hill, NC, USA; and §§ Malm€o Centre for Thrombosis and
Haemostasis, Skane University Hospital, Lund University, Malm€o, Sweden
To cite this article: Abshire T, Cox-Gill J, Kempton CL, Leebeek FWG, Carcao M, Kouides P, Donfield S, Berntorp E. Prophylaxis escalation in
severe von Willebrand Disease: a prospective study from the von Willebrand Disease Prophylaxis Network. J Thromb Haemost 2015; 13:
1585–9.
See also Federici AB. Prophylaxis in patients with von Willebrand disease: who, when, how? This issue, pp 1581–4.
Summary. Background: Treatment of mucosal bleeding
(epistaxis, gastrointestinal bleeding, and menorrhagia) and
joint bleeding remains problematic in clinically severe von
Willebrand disease (VWD). Patients are often unrespon-
sive to treatment (e.g. desmopressin or antifibrinolytic
therapy) and may require von Willebrand factor (VWF)
replacement therapy. There are little data on the use of
prophylaxis in VWD, and none have been applied in a
prospective, treatment escalation design. Objective: Evalu-
ate the effect of escalating dose prophylaxis in severe
VWD. Methods: Patients eligible for enrollment in this
prospective study included those with type 1 VWD with
VW factor activity–ristocetin cofactor ratio ≤ 20% and
unresponsive to desmopressin, patients with type 2
VWD not responsive to desmopressin and all sub-
jects with type 2B and type 3 VWD. Entry criteria
were strictly defined, as were therapy escalation
parameters and clinical data collection. Results: Eleven
subjects completed the study. Six had type 2A, and five
had type 3 VWD. Six patients presented with epistaxis,
three with GI bleeding, and two with joint bleeding.
Seven had dose escalation above the first level. Among
the 10 subjects with evaluable bleeding log data, use of
prophylaxis decreased the median annualized bleeding
rate from 25 to 6.1 (95% confidence interval of the rate
difference: 51.6 to 1.7), and the median annualized
bleeding rate was even lower (4.0; 95% confidence inter-
val: 57.5 to 5.3) when the subjects reached their final
dosing level. Conclusion: This is the first prospective
study to demonstrate that prophylaxis with VW factor
concentrates is highly effective in reducing mucosal and
joint bleeding rates in clinically severe VWD.
Keywords: epistaxis; gastrointestinal hemorrhage;
hemarthrosis; prophylaxis; von Willebrand disease.
Introduction
Management of bleeding patterns remains problematic
for certain cases of severe von Willebrand disease
(VWD). These are chiefly mucosal, such as epistaxis, gas-
trointestinal (GI) bleeding, and menorrhagia, but can also
involve the type of bleeding more commonly observed in
moderate hemophilia such as joint hemorrhage. Previous
studies have confirmed these bleeding manifestations in
VWD [1]. The symptoms may not respond to treatment
approaches such as desmopressin, antifibrinolytic therapy,
or oral contraceptives, necessitating the use of von Wille-
brand factor (VWF)-containing plasma-derived products.
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The VWD International Prophylaxis (VIP) Study is an
initiative of the multicenter von Willebrand Disease Pro-
phylaxis Network (VWD PN). The goal of the VIP study
is to examine the effect of regular replacement therapy as
prophylaxis in clinically severe VWD that is unresponsive
to other treatment(s).
Prophylaxis is common in the treatment of hemophilia,
but there are little data on its use in VWD, with the few
retrospective studies all demonstrating a reduction in
bleeding rates [2–4]. Recent data from a retrospective
study completed by the VWD PN provide strong support
for the use of prophylaxis for epistaxis, GI bleeding, men-
orrhagia, and joint bleeding among those most severely
affected [5]. The authors now describe efforts to evaluate
the effect of prophylaxis for joint bleeding, GI bleeding,
excessive bleeding during menses, and epistaxis in a pro-
spective, treatment escalation study. The objectives of this
study were to (i) address the effect of prophylaxis on
bleeding frequency in severe VWD and (ii) establish opti-
mal treatment regimens (dose and frequency) for the
bleeding indications just noted. This report is the first to
prospectively evaluate the use of prophylaxis in VWD.
Methods
Population inclusion
Subjects were required to meet criteria for severe forms of
VWD, as well as to demonstrate patterns of bleeding spe-
cific to one of the indications under investigation. Patients
with type 1 VWD were eligible for participation if the
VW factor activity–ristocetin cofactor ratio (VWF:RCo)
was ≤ 20% and/or factor VIII (FVIII) ≤ 20%; b) the
patients were desmopressin non-responsive, defined as
occurrence of bleeding episodes not responding satisfacto-
rily to desmopressin, or deemed non-responsive a priori
by the investigator. Subjects with type 2 VWD of all
subtypes were eligible if they were desmopressin non-
responsive or deemed non-responsive a priori by the
investigator. All patients with type 2B and type 3 VWD
were eligible. Patients were diagnosed locally at their
centers.
Criteria for inclusion by bleeding indication were
defined as (i) joint bleeding―documentation of at least
two spontaneous bleeding episodes in the same joint with-
out evidence of trauma during the 6 months before
enrollment or three or more spontaneous bleeding epi-
sodes in different joints in the 6 months before enroll-
ment; (ii) GI bleeding―history of two or more severe GI
bleeding episodes with no identifiable cause, associated
with either a drop in hemoglobin of ≥ 2 g dL1 or requir-
ing a red blood cell transfusion or treatment with a
VWF-containing concentrate; (iii) excessive bleeding dur-
ing menstruation―a diagnosis of menorrhagia was
defined by a prospectively completed Pictorial Blood
Assessment Chart (PBAC) score > 185 and normal cervi-
cal cytology or requiring use of a VWF-containing con-
centrate for treatment of excessive menstrual bleeding for
at least one menstrual cycle during the prior year; and
(iv) epistaxis―defined as three or more bleeding episodes
in a 6-month period that required treatment with a VWF-
containing concentrate or a red blood cell transfusion.
Criteria for exclusion
Subjects were excluded if they had acquired von Wille-
brand syndrome, had a history of an inhibitor, were on
prophylaxis for > 3 months in the year before enrollment,
or had a history of non-compliance. Data were collected
between 2008 and 2012. The human subjects committees
of collaborating institutions approved the VIP study in
compliance with the guidelines of the Declaration of Hel-
sinki. The study is registered at www.ClinicalTrials.gov
(NCT00557908).
Treatment escalation
Criteria for escalation were specific to each bleeding indi-
cation (Table 1) but, overall, involved one significant
breakthrough bleeding episode despite compliant prophy-
laxis. Subjects entering the study began at treatment level
1: 50 IU VWF:RCo/kg once/week and remained on this
dose until meeting the criteria for escalation to level 2:
two infusions of 50 IU VWF:RCo/kg/week, or level 3:
three infusions of 50 IU VWF:RCo/kg/week.
Clinical data collection
Variables collected included demographics, VWD type,
site and frequency of bleeding episodes before, and after,
the initiation of prophylaxis. The bleeding history was
derived from center records or registries, diaries, and logs.
Following enrollment, data related to bleeding episodes
and frequency of infusions were recorded in diaries main-
tained by the subject. Treatment of acute bleeding epi-
sodes and management of treatment failure, such as
severe breakthrough bleeding not adequately controlled
by the dose escalation schedule, were at the discretion of
the investigator. The type of product used for prophylaxis
was at the discretion of the investigator as well, and the
VWF product was not provided as part of the study. The
duration of follow-up was 1 year.
Statistical methods
Annualized bleeding rates were calculated for the periods
before and during prophylaxis. For the prophylaxis per-
iod, annualized bleeding rates were calculated for the
total time on prophylaxis and for the time at the final
treatment level. A ‘paired’ approach was used to calculate
the change in annualized bleeding rate within individuals
by subtracting the number of events that occurred before
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prophylaxis from the number of bleeds during prophy-
laxis. A paired Wilcoxon signed rank test of the differ-
ences in the medians was used to compare the bleeding
rates. The limited sample size did not permit comparison
of bleeding rates by indication for each level of treatment
or analysis of timing or patterns of escalation.
Results and discussion
Thirteen subjects were enrolled from seven centers in
North America and Europe. Two subjects withdrew from
the study immediately after enrollment and are not
included in the analysis: one decided not to participate
and one had clinical indications for more intensive treat-
ment. Eleven completed the protocol. Sixty-four percent
of these were male (seven participants), and 36% were
female (four participants). The median age (range) at
enrollment was 34.6 (3.1–80.6 years). Participants were
predominantly white (63.6%) or of African descent
(18.2%). Six had type 2A VWD, and five had type 3.
The primary indications for enrollment among those
completing the study were epistaxis (six participants), GI
bleeding (three participants), and joint bleeding (two par-
ticipants). The majority of those with epistaxis were chil-
dren, while GI bleeding occurred among older
participants. There were no patients enrolled for treat-
ment of menorrhagia. As shown in Table 2, seven partici-
pants had escalated beyond treatment level 1 by the end
of follow-up, and the four patients who remained at the
entry level dose and interval were treated for epistaxis.
Details of trough FVIII:C and VWF:RCo and final treat-
ment level are provided in Table 3.
Bleeding logs were reviewed for accuracy by center per-
sonnel and at the data and statistical coordinating center.
Logs for 10 of the 11 participants were usable for the
analysis of change in bleeding rates; bleeding episodes
and infusions for the 11th participant were too inconsis-
tently reported to be reliable. Before the onset of prophy-
laxis, the median (IQR) annualized bleeding rate was 25.0
(12.0–51.2). This bleeding frequency decreased to a med-
ian (IQR) of 6.1 (3.1–29.0) during prophylaxis
(P = 0.027); 95% confidence interval (CI) of the rate dif-
ference: 51.6 to 1.7. However, the median (IQR)
annualized bleeding rate was even lower (4.0, 0–27.7);
P = 0.0098, CI: 57.5 to 5.3, when comparing the rate
before initiation of prophylaxis with that observed during
the interval after the participant had reached his/her final
treatment level.
This is the first study to demonstrate, in a prospec-
tive manner, that prophylaxis with appropriate stepwise
dose escalation is beneficial in patients with clinically
severe VWD. The number of subjects enrolled in this
prospective study was far fewer than planned and too
few to achieve one of the study objectives, namely to
establish the optimal prophylactic treatment regimen for
four common types of bleeding in VWD. Nonetheless,
it appears that the first dose level (50 IU VWF:RCo/kg
once/week) was effective in the majority of the enrolled
patients with epistaxis (four of six subjects). Because
most of those treated for epistaxis were younger, once/
week dosing for this population may be advantageous.
Additionally, two other problematic VWD bleeding
conditions, GI and joint bleeding, demonstrated bleed-
Table 1 Criteria for escalation specific to each bleeding indication
Joint Bleeding
Level 1: 50 IU VWF:RCo/kg (rounded up to the nearest vial) once/
week. In the event a spontaneous joint bleeding episode occurs
while on this regimen, the subject will escalate to the level 2 dose
following its resolution
Level 2: 50 IU VWF:RCo/kg (rounded up to the nearest vial) twice/
week. In the event a spontaneous joint bleeding episode occurs
while on this regimen, the subject will escalate to the level 3 dose
following its resolution
Level 3: 50 IU VWF:RCo/kg (rounded up to the nearest vial) three
times/week
GI Bleeding
Level 1: 50 IU VWF:RCo/kg (rounded up to the nearest vial) once/
week. In the event a severe* GI bleeding episode occurs while on
this regimen, the subject will escalate to the level 2 dose following
its resolution
Level 2: 50 IU VWF:RCo/kg (rounded up to the nearest vial) twice/
week. In the event a severe* GI bleeding episode occurs while on
this regimen, the subject will escalate to the level 3 dose following
its resolution
Level 3: 50 IU VWF:RCo/kg (rounded up to the nearest vial) three
times/week
Menorrhagia
Level 1: 50 IU VWF:RCo/kg (rounded up to the nearest vial) on
day 1 of menses for two cycles. Menstrual flow will be monitored
by the PBAC score. If the average pictorial chart score is > 185,
then the subject will escalate to the level 2 dose
Level 2: 50 IU VWF:RCo/kg (rounded up to the nearest vial) on
days 1 and 2 of menses for two cycles. Menstrual flow will be
monitored by the PBAC score. If the average pictorial chart score
is > 185, then the subject will escalate to the level 3 dose
Level 3: 50 IU VWF:RCo/kg (rounded up to the nearest vial) on
days 1, 2, and 3 of menses. Menstrual flow will be monitored by
pictorial chart
Epistaxis
Level 1: 50 IU VWF:RCo/kg (rounded up to the nearest vial) once/
week. The subject will escalate to the level 2 dose in the event of
one occurrence of breakthrough bleeding requiring intervention
such as iron replacement therapy, transfusion, packing,
hospitalization; or two bleeding events that require treatment with
factor replacement
Level 2: 50 IU VWF:RCo/kg (rounded up to the nearest vial) twice/
week. The subject will escalate to the level 3 dose in the event of
one occurrence of breakthrough bleeding requiring intervention
such as iron replacement therapy, transfusion, packing,
hospitalization; or two bleeding events that require treatment with
factor replacement
Level 3: 50 IU VWF:RCo/kg (rounded up to the nearest vial) three
times/week
A subject’s compliance with the prescribed regimen should be evalu-
ated as part of the treating physician’s decision to escalate to the
next dose. Specific days of treatment administration will be at the
discretion of the investigator, with a goal of optimizing levels of
VWF. *Defined as GI bleeding associated with either a drop in
hemoglobin of ≥ 2 g dL1 or requiring RBC transfusion.
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ing reduction at a less than maximum dosing level.
This is similar to results from another dose and interval
treatment escalation study, the Canadian Hemophilia
Primary Prophylaxis Study Group [6]. Three patients
from the current study required the maximum dosing
interval and one required tailored higher dosing and
frequency.
The annualized bleeding rate was significantly lower,
decreasing from a median of 25.0, before prophylaxis, to
4.0 when regular infusions of VWF concentrate were
given, a finding that confirms prior retrospective studies.
Additionally, it is important to note that controlled dose
escalation achieved significant reduction in bleeding in the
overall study group, which suggests that a stepwise
approach to treatment intervention can be applied to this
clinically severe VWD population.
Data to support prophylaxis in subjects with VWD
come from a multicenter population-based study con-
ducted in Sweden in a group of 52 subjects with clini-
cally severe VWD [2]. Thirty-nine of these were on
long-term prophylaxis and 13 were treated on-demand.
The method of treatment was based on clinical criteria
(i.e., patterns of bleeding). Results of the study showed
that participants beginning prophylaxis at a young age
(< 5 years) had few or no bleeding episodes, and none
had clinical signs of arthropathy or ongoing joint bleed-
ing. Older participants beginning prophylaxis at
> 15 years of age usually reported a substantial reduc-
tion in joint bleeding but had clinical and radiological
signs of joint disease. Reductions in other types of
bleeding, including epistaxis, were also demonstrated.
The investigators concluded that long-term prophylactic
treatment in VWD is warranted in the majority of cases
with type 3 disease, and in some cases for those with
other VWD variants.
Reports from industry sponsored trials investigating
the efficacy of bleed reduction from VWF concentrates
have also demonstrated similar results as the study dis-
cussed and in the previously noted retrospective studies
[7–10]. Similarly, a recent retrospective study from the
VWD PN also demonstrated efficacy [5]. In the latter
study, prophylaxis had the greatest impact in reducing
joint bleeding (~90% reduction), supporting the observa-
tions cited earlier [2]. Mucosal bleeding such as epistaxis
and GI bleeding also showed a reduction after initiation
of prophylaxis but to a lesser extent (50–55%).
There were four major barriers to enrollment, as fol-
lows: (i) Lack of optimal candidates for study. Patients
with more severe forms of VWD were either already on
prophylaxis or, in some cases, bleeding symptoms were
not severe or persistent enough for study enrollment. (ii)
Dose escalation schedule was not embraced by partici-
pating institutions. These investigators expressed a pref-
erence for individualizing treatment rather than adhering
to a standardized dose and interval schedule. This con-
cern is often cited as one reason for the lack of investi-
gator initiated clinical trials in bleeding disorders but for
those subjects enrolled in this study, the efficacy of a
stepwise dosing and interval treatment approach was
encouraging. (iii) Lack of providing a VWF containing
product for study patients. (iv) Lack of insurance cover-
age for some subjects who were considering prophylaxis.
This lagging insurance provider support was evident
despite the well known use of prophylaxis in VWD for
at least a decade in Europe coupled with the frequent
off-label use of VWF/FVIII products for treatment of
the clinically severe patients with VWD in the United
States.
A strength of this investigation is that it shows that a
multicenter, dose-escalation prospective study can be con-
Table 2 Final treatment level by VWD type and bleeding indication
Treatment level 1 Treatment level 2 Treatment level 3 Escalated beyond level 3*
Type Bleeding indication Type Bleeding indication Type Bleeding indication Type Bleeding indication
2A Epistaxis 2A Epistaxis 2A Epistaxis 2A GI bleeding
2A Epistaxis 3 GI bleeding 3 Joint bleeding
3 Epistaxis 3 Joint bleeding 2A GI bleeding
3 Epistaxis
*Regimen escalated to one infusion (75 IU VWF:RCo/kg) every other day.
Table 3 Trough FVIII:C and VWF: RCo levels at enrollment and
final treatment levels
VWD
type
Primary
indication
Final
treatment
level
FVIII:C
trough
(IU dL1)
VWF:RCo
trough
(IU dL1)
2A Epistaxis Level 1 102 < 10
2A Epistaxis Level 3 94 < 10
2A GI bleeding Every
other day
77 51
3 Epistaxis Level 1 3 < 20
3 Joint bleeding Level 3 4 < 10
2A Epistaxis Level 2 80 17
2A Epistaxis Level 1 44 10
3 Epistaxis Level 1 4 < 5*
2A GI bleeding Level 3 47 11
3 Joint bleeding Level 2 2 < 10*
3 GI bleeding Level 2 4 < 5
*Measurement of trough levels was conducted at enrollment after a
washout period of at least 72 h. Values indicated by ‘*’ are baseline
levels obtained before study enrollment.
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ducted across centers in Europe and North America.
Unfortunately, evaluation of so few subjects resulted in
insufficient statistical power to meet the primary objective
of establishing optimal treatment regimens for the most
common bleeding conditions in clinically severe VWD.
Nonetheless, we were able to demonstrate a significant
effect of prophylaxis in reducing bleeding in the overall
cohort. These findings provide support for the use of pro-
phylaxis in the context of treatment escalation in severe
VWD and should encourage further investigation.
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